HK1174259B

HK1174259B - Multivalent pneumococcal polysaccharide-protein conjugate composition

Info

Publication number: HK1174259B
Application number: HK13101295.5A
Authority: HK
Inventors: William P. Hausdorff; George Rainer Siber; Peter R. Paradiso
Original assignee: 惠氏有限责任公司
Priority date: 2005-04-08
Filing date: 2013-01-30
Publication date: 2023-05-12

Description

Multivalent pneumococcal polysaccharide-protein conjugate composition

The application is a divisional application of Chinese patent application 200680017776.8 (International application No. PCT/US 2006/012354) with the filing date of 2006, 3 and 31, and the title of the invention is "multivalent pneumococcal polysaccharide-protein conjugate composition".

Technical Field

The present invention relates generally to the field of medicine, and more particularly to microbiology, immunology, vaccines and prevention of infection by bacterial pathogens by immunization.

Background

Streptococcus pneumoniae (Streptococcus pneumoniae) is a major cause of meningitis, pneumonia and severely invasive diseases in infants and young children worldwide. Multivalent pneumococcal polysaccharide vaccines have been approved many years ago and have proven valuable in preventing pneumococcal disease in the elderly and in high-risk patients. However, infants and young children respond poorly to most pneumococcal polysaccharides. A 7-valent pneumococcal conjugate vaccine (7 vPnC,) Is the first vaccine to demonstrate high immunogenicity and efficacy against invasive diseases and otitis in infants and young children. TheVaccines are now approved in many countries around the world. Prevnar contains capsular polysaccharides from serotypes 4, 6B, 9V, 14, 18C, 19F and 23F, each conjugated to what is called CRM ₁₉₇ The carrier protein of (1). Prevnar covers approximately 80-90%, 60-80% and 40-80% Invasive Pneumococcal Disease (IPD) [1,2] in the United states, europe and other parts of the world, respectively]. Monitoring data collected years after the introduction of Prevnar has clearly shown a reduction in invasive pneumococcal disease in american infants as expected (figure 1) [3,4 |)]。

IPD monitoring in US infants prior to the introduction of Prevnar indicated that the majority of the disease due to serogroups 6 and 19 was due to serotypes 6A (about 1/3) and 19A (about 1/4) [5,6]. After Prevnar approval, pneumococcal invasive disease surveillance in the united states showed that most of the disease is still due to serotypes 6A and 19A (fig. 1) [3]. In addition, these two serotypes cause more invasive disease cases than the sum of serotypes 1,3, 5, and 7F (8.2 vs. 3.3 in 100,000 children under 2 years of age). In addition, serotypes 6A and 19A are associated with a high rate of antibiotic resistance (fig. 2) [7,8,9]. Although it is likely that serogroup cross-protection will lead to a decline in serotype 6A and 19A disease as more children are immunized, there is evidence that the decline will be limited and a significant burden of disease due to these serotypes will remain (see below).

Given the relative burden and importance of invasive pneumococcal disease due to serotypes 1,3, 5, 6A, 7F and 19A, the addition of these serotypes to Prevnar formulations will increase the coverage of invasive disease to >90% in the united states and europe, and up to 70% -80% in asia and latin america. This vaccine would significantly extend coverage of Prevnar and provide coverage for 6A and 19A, independent of the limitations of serogroup cross-protection.

Summary of The Invention

Accordingly, the present invention generally provides a multivalent immunogenic composition comprising 13 different polysaccharide-protein conjugates, wherein each conjugate comprises a capsular polysaccharide from a different serotype of streptococcus pneumoniae conjugated to a carrier protein, and a physiologically acceptable carrier. Optionally, an adjuvant, such as an aluminum-based adjuvant, is included in the formulation. More particularly, the invention provides 13-valent pneumococcal conjugate (13 vPnC) compositions comprising 7 serotypes of a 7vPnC vaccine (4, 6B, 9V, 14, 18C, 19F and 23F) plus 6 additional serotypes (1, 3,5, 6A, 7F and 19A).

The invention also provides a multivalent immunogenic composition, wherein the capsular polysaccharides are from serotypes 1,3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F of streptococcus pneumoniae and the carrier protein is CRM ₁₉₇ 。

The invention also provides a multivalent immunogenic composition, wherein the capsular polysaccharides are serotypes 1,3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F of Streptococcus pneumoniae, and the carrier protein is CRM ₁₉₇ And the adjuvant is an aluminum-based adjuvant such as aluminum phosphate, aluminum sulfate and aluminum hydroxide. In a particular embodiment of the invention, the adjuvant is aluminium phosphate.

The invention also provides a multivalent immunogenic composition comprising polysaccharide-protein conjugates and a physiologically acceptable carrier, wherein each conjugate comprises a capsular polysaccharide from a different serotype of streptococcus pneumoniae conjugated to a carrier protein, and the capsular polysaccharides are prepared from serotype 3 and at least one additional serotype.

In one embodiment of the multivalent immunogenic composition, the additional serotype is selected from serotypes 1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. In another embodiment, the carrier protein is CRM ₁₉₇ . In yet another embodiment, the composition comprises an adjuvant, such as an aluminum-based adjuvant selected from the group consisting of aluminum phosphate, aluminum sulfate, and aluminum hydroxide. In a specific embodiment, the adjuvant is aluminum phosphate.

The invention also provides a multivalent immunogenic composition comprising polysaccharide-protein conjugates together with a physiologically acceptable carrier, wherein each conjugate comprises a capsular polysaccharide from a different serotype of streptococcus pneumoniae conjugated to a carrier protein, and the capsular polysaccharides are prepared from serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and at least one additional serotype.

In one embodiment of the multivalent immunogenic composition, the additional serotype is selected from serotypes 1,3, 5, 6A, 7F, and 19A. In another embodiment, the carrier protein is CRM ₁₉₇ . In yet another embodiment, the composition comprises an adjuvant, such as an aluminum-based adjuvant selected from the group consisting of aluminum phosphate, aluminum sulfate, and aluminum hydroxide. In a specific embodiment, the adjuvant is aluminum phosphate.

The invention also provides a method of inducing an immune response to a streptococcus pneumoniae capsular polysaccharide conjugate comprising administering to a human an immunologically effective amount of any one of the immunogenic compositions described above.

The invention also provides that any one of the immunogenic compositions administered is a single 0.5mL dose formulated to contain: 2 μ g of each saccharide, except 4 μ g of 6B; about 29 μ g CRM ₁₉₇ A carrier protein; 0.125mg elemental aluminum (0.5 mg aluminum phosphate) adjuvant; and sodium chloride and sodium succinate buffers as excipients.

Brief Description of Drawings

Fig. 1 depicts the change in IPD ratio by serotype from baseline (1998/1999) to 2001 in children <2 years of age in the united states.

FIG. 2 depicts the distribution of Penicillin (PCN) -resistant Streptococcus isolates in children <5 years of age (1998).

FIG. 3 depicts the Reciprocal Cumulative Distribution Curve (RCDC) of OPA after the third dose from the D118-P16 Prevnar trial.

Detailed Description

Inclusion of Prevnar serotypes 4, 6B, 9V, 14, 18C, 19F, 23F

Data from IPD monitoring between 1995-1998 estimated that 7 serotypes in Prevnar contribute to IPD in about 82% of children <2 years of age [5]. At the northern efficacy testing site of California, prevnar serotype accounts for 90% of all IPD cases in infants and young children [10]. Since the introduction of the Prevnar vaccine in 2000, the overall IPD rate has decreased significantly due to the decline in disease caused by this vaccine serotype [3,4]. Thus, there is no reason at this point to remove any Prevnar serotype from the next generation pneumococcal conjugate vaccine, but rather to add serotypes for wider coverage.

Inclusion of serotypes 1,3, 5 and 7F

In the united states, serotype 1 causes IPD rates <2% in children under 5 years of age, and is approximately the same for each of serotypes 3 and 7F [1,6]. Serotypes 1 and 5 account for the higher incidence of IPD in the high-risk us population with invasive pneumococcal disease. In particular, serotype 1 causes 3.5% of IPD in native children <2 years of age, alaska, and 18% of IPD in children 2-4 years of age [11]. Serotype 1 and serotype 5 are significantly pathogenic in the indigenous population of other parts of the world and in developed countries [12,13,14].

Serotype 1 is also associated with more severe disease than other pneumococcal serotypes [15]. The observation is based on the difference in case identification rates between the us and europe, and the differences associated with medical practice. Overall, the incidence of IPD is lower in europe than in the united states. However, the percentage of IPD induced by serotype 1 in Europe is disproportionately higher than in the United states (6-7% and 1-2%, respectively). In europe, blood cultures are mainly obtained from hospitalized children. It is common medical practice in the United states to obtain blood cultures from children who have fever ≧ 39 ℃ and elevated leukocyte counts in outpatients. Given the differences in medical practice, it is speculated that a lower percentage of disease caused by serotype 1 in the united states may be diluted at a higher rate by other serotypes causing less disease, while a higher percentage in europe reflects more severe disease. In addition, seroepidemiological studies in children with complicated pneumonia have shown that serotype 1 is disproportionately represented [16,17,18]. This suggests that inclusion of serotype 1 may reduce the amount of severe pneumococcal disease, as well as promote an overall reduction in invasive pneumococcal disease.

The addition of serotypes 3 and 7F will increase IPD coverage by about 3% -7% in most parts of the world, and about 9% in asia. Thus, the 11-valent vaccine will cover about 50% of the IPD in asia and about 80% in all other regions [1,2]. These serotypes are also important for otitis media coverage [19]. In a multi-national study of pneumococcal serotypes responsible for otitis media, hausdorff et al found that serotype 3 was the most prevalent overall middle ear fluid isolate at position 8 [20]. Serotype 3 accounts for up to 8.7% of pneumococcal serotypes associated with otitis media. Thus, the importance of serotypes 3 and 7F in otitis media as well as IPD warrants their inclusion in pneumococcal conjugate vaccines.

However, attempts to generate multivalent pneumococcal conjugate vaccines with significant immunogenicity for serotype 3 polysaccharides have not been successful. For example, in immunogenicity and safety studies of 11-valent pneumococcal protein D conjugate vaccine (11-Pn-PD), no priming effect of serotype 3 was observed in infants receiving three doses of vaccine followed by booster doses of the same vaccine or pneumococcal polysaccharide vaccine (Nurkka et al (2004) ped. Inf. Dis.j., 23. In another study, the opsonophagocytosis assay (OPA) from infants who had received 11-Pn-PD doses did not show an antibody response to serotype 3 at levels comparable to other serotypes tested (Gatchalan et al, 17) ^th Annual Meeting of the Eur. Soc. Paed. Inf. Dis. (ESPID), poster No.4, P1A Poster Session 1, istanbul Turkey, mar.27, 2001). In a further study, the efficacy of 11-Pn-PD in the prevention of acute otitis media was assessed and the vaccine did not provide protection against serotype 3-induced seizures (Prymula et al www.thelancet.com.Vol.367:740-748 (March 4,2006)). Accordingly, a pneumococcal conjugate vaccine comprising a capsular polysaccharide from serotype 3 and capable of eliciting an immunogenic response to serotype 3 polysaccharide provides a significant advance in the state of the art.

Inclusion of serotypes 6A and 19A

a. Epidemiology of serotypes 6A and 19A

Surveillance data in the literature suggest that serotypes 6A and 19A cause more invasive pneumococcal disease in children <2 years of age in the united states (figure 1) than serotypes 1,3, 5, and 7F in combination [1,5]. Furthermore, these serotypes are often associated with antibiotic resistance (fig. 2) and play an important role in otitis media [6,19,20]. The ability of the current Prevnar vaccine to protect against diseases caused by 6A and 19A is not clear. The principle of including the 6A and 19A components in the 13vPnC vaccine is discussed below.

b.6B and 19F polysaccharide-induced responses to 6A and 19A

An approved unconjugated pneumococcal polysaccharide vaccine (for use in humans at least 2 years of age) already contains the 6A or 6B capsular polysaccharide, but not both [21]. The immunogenicity data generated when formulating the 23 valent pneumococcal polysaccharide vaccine indicates that the 6B monovalent vaccine induces antibodies against the 6A and 6B capsules. Data from several experiments evaluating IgG and opsonophagocytosis assay (OPA) responses in various populations using free polysaccharide and using pneumococcal conjugate vaccines indicate that IgG responses to 6A are induced by the 6B antigen, but that the response is generally lower and that OPA activity using 6A organisms differs from that using 6B organisms [22,23,24,25]. Furthermore, subjects who respond with high 6B antibodies may have little or no activity on 6A.

Compared to the chemical composition of the 6A and 6B capsular polysaccharides, where there is a high degree of similarity, the 19A and 19F capsules differ considerably due to the presence of two additional side chains in the 19A polysaccharide. Not surprisingly, the immune response measured in human volunteers immunized with the 19F polysaccharide vaccine showed that a response to 19F was induced in 80% of the subjects, but only in 20% of the subjects [26]. Low levels of cross-reactive IgG and OPA responses to serotype 19A following immunization with 19F polysaccharide have also been documented in experiments using conjugate vaccines [24,26].

Internal data on cross-reactive OPA responses to 16A and 19A have been generated from the 7vPnC bridging test (D118-P16) performed in us infants (fig. 3). These studies are consistent with the findings of others and indicate that cross-reactive functional antibodies to 6A polysaccharide are induced after immunization with 6B polysaccharide, albeit at a lower level, and very low functional antibodies to 19A after immunization with 19F.

Effect of 6B and 19F immunization on 6A and 19A in animal models

Animal models have been used to assess the potential for cross-protection by immunization with polysaccharides. In the otitis media model developed by Giebink et al, gray mice were immunized with tetravalent polysaccharide Outer Membrane Protein (OMP) conjugate vaccine (containing 6B, 14, 19F, 23F sugars) or placebo [27]. In this test, there appears to be some cross-protection for 6A; however, this did not reach statistical significance and the level of protection was lower than that of otitis media with 6B. In this same model, there was 100% protection against 19F otitis media, but only 17% protection against 19A otitis media.

Saeland et al passively immunized mice in a lung infection model with infant sera from immunization with an 8-valent pneumococcal tetanus conjugate vaccine (containing 6B and 19F) followed by intranasal challenge with 6A organisms [28]. Of the 59 serum samples, 53% protected mice against bacteremia with 6B and 37% protected against 6A. Mice passively immunized with sera from infants immunized with 4 doses of the 11-valent pneumococcal conjugate vaccine (containing 19F conjugated to tetanus toxoid) were given an intranasal challenge of 19A organisms in the same model [29]. Of the 100 passively immunized and then challenged mice, 60 mice did not detect 19A organisms in lung tissue, whereas organisms were identified in all mice given saline placebo. However, in this model, passive immunization cannot protect against challenge with 19F organisms; therefore, the correlation of this model to serogroup 19 is questionable. In general, these models provide evidence for some biological effect of 6B immunity on 6A organisms, although the effect on heterologous serotypes is not as great as that observed with homologous serotypes. The effect of 19F immunization on 19A organisms is not well understood from these models.

Effect of 6B and 19F polysaccharide conjugate immunization on 6A and 19F disease in efficacy/efficacy assays

The number of disease cases due to serotypes 6B, 6A, 19F and 19A in the efficacy trials of 7vPnC and 9vPnC (7 vPnC plus serotypes 1 and 5) is indicated in table 1 [30,10,31]. The number of cases of invasive disease was too small to draw any conclusions about serotypes 6A and 19A. However, the Finnish otitis media trial produced many pneumococcal isolates [32]. In a protocol analysis (per protocol analysis), 7vPnC was 84% (95% cl 62%, 93%) effective for otitis media due to serotype 6B and 57% (95% cl 24%, 76%) effective for otitis media due to serotype 6A (table 1). In contrast, no serotype specific efficacy with 7vPnC was demonstrated for otitis media due to 19F or 19A.

TABLE 1 cases of pneumococcal disease due to serotypes 6B, 6A, 19F and 19A in efficacy trials using 7vPnC and 9vPnC vaccines

* Elucidation of statistically significant efficacy

From references 30,10 and 33, with personal communication

Contr = control

ITT = intended treatment analysis

PP = compliance protocol analysis

Post-market IPD monitoring data can also be obtained from case-Control trials conducted by Centers for Disease Control [33] to assess the effectiveness of Prevnar. Cases of pneumococcal invasive disease in children 3 to 23 months of age were identified in the surveillance laboratory and matched with three control cases by age and zip code. After informed consent, medical and immunization history (subjects were considered immunized if they received at least one dose of Prevnar) was obtained from parents and medical providers of the cases and controls. Preliminary results are given at the 2003 ICAAC conference and a summary of findings for 6B, 19F, 19A and 6A diseases is given in Table 2. These data indicate that Prevnar is able to prevent disease due to 6A, although at a level somewhat lower than serotype 6B disease. These data also indicate that cross-protection against invasive disease due to 19A is limited.

TABLE 2 preliminary results of case control experiments performed by CDC (given on ICAAC 2003)

* Comparison of effectiveness of vaccinated (> 1 dose) versus unvaccinated vaccines and modulation of potential conditions

REFERENCE 40 AND PERSONAL/SECTIONAL COMMUNICATION

Published analysis used by Prevnar [3] also showed that serotypes 6A and 19A confer modest reductions in IPD caused by serotypes 6B and 19F in children under the age of 2 (table 1 in [3 ]). There was some reduction in the incidence of disease in non-immunized adults caused by serotypes 6A, 9L, 9N, 18A, 18B, 18F, 19A, 19B, 19C, 23A, and 23B ("all vaccine-related serotypes") ([ 2 in [3 ]). These data establish that population immunity using Prevnar in children under the age of 2 is moderate for serotypes 6A and 19A, and provide the basis for including serotypes 6A and 19A in the 13vPnC vaccines of the invention.

Conclusion of addition of 6A and 19A

Post-market surveillance data and case-control studies using the 7vPnC vaccine in fig. 1 and table 2 show that, consistent with the other information described above regarding immune response and performance in animals, there may be some cross-protection against the 6A disease, but to a lesser extent than the 6B disease. Furthermore, it appears that the protection of 19A is limited. Thus, 13vPnC vaccines containing serotypes 6A and 19A provide coverage that is independent of the limitations of serogroup cross-protection by serotypes 6B and 19F.

Accordingly, the present invention provides a multivalent immunogenic composition comprising 13 different polysaccharide-protein conjugates, wherein each conjugate contains a different capsular polysaccharide conjugate conjugated to a carrier protein, and wherein the capsular polysaccharides are prepared from serotypes 1,3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F of streptococcus pneumoniae, and a physiologically acceptable carrier. One such carrier protein is known as CRM ₁₉₇ Diphtheria toxoid of (2). The immunogenic composition may further comprise an adjuvant, such as an aluminum-based adjuvant, such as aluminum phosphate, aluminum sulfate and aluminum hydroxide.

The capsular polysaccharides are prepared by standard techniques known to those skilled in the art. In the present invention, capsular polysaccharides are prepared from serotypes 1,3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F of Streptococcus pneumoniae. These pneumococcal conjugates are prepared by a separate method and formulated into a single dose formulation. For example, in one embodiment, each pneumococcal polysaccharide serotype is cultured in a soy-based medium. The various polysaccharides were then purified by centrifugation, precipitation, ultrafiltration and column chromatography. The purified polysaccharide is chemically activated to enable the saccharide to react with the carrier protein.

Once activated, each capsular polysaccharide is conjugated individually to a carrier protein to form a complex saccharide. In one embodiment, each capsular polysaccharide is conjugated to the same carrier protein. In this embodiment, conjugation is achieved by reductive amination.

Chemical activation of the polysaccharide and subsequent conjugation to the carrier protein is achieved by conventional methods. See, for example, U.S. Pat. Nos. 4,673,574 and 4,902,506[34,35].

The carrier protein is preferably a non-toxic and non-reactogenic protein and may be obtained in sufficient quantity and purity. The carrier protein should be subjected to standard conjugation procedures. In a particular embodiment of the invention, CRM is used ₁₉₇ Used as a carrier protein.

CRM ₁₉₇ (Wyeth, sanford, NC) is a non-toxic variant (i.e., toxoid) of diphtheria toxin isolated from a culture of Corynebacterium diphtheriae (Corynebacterium diphtheria) strain C7 (. Beta.197) grown in casamino acids and yeast extract-based medium. Purification of CRM by ultrafiltration, ammonium sulfate precipitation and ion exchange chromatography ₁₉₇ . Alternatively, CRM was recombinantly produced according to U.S. Pat. No. 5,614,382 ₁₉₇ This patent is incorporated herein by reference. Other diphtheria toxoids are also suitable as carrier proteins.

Other suitable carrier proteins include inactivated bacterial toxins such as tetanus toxoid, pertussis toxoid, cholera toxoid (e.g. [38] as described in international patent application WO 2004/083251), escherichia coli LT, escherichia coli ST, and exotoxins from Pseudomonas aeruginosa (Pseudomonas aeruginosa). Bacterial outer membrane proteins such as outer membrane complex C (OMPC), porins, transferrin binding proteins, pneumolysin, pneumococcal surface protein a (PspA), pneumococcal adhesion protein (PsaA), C5a peptidases from group a or group B streptococci, or haemophilus influenzae protein D may also be used. Other proteins, such as ovalbumin, keyhole Limpet Hemocyanin (KLH), bovine Serum Albumin (BSA) or purified protein derivatives of tuberculin (PPD) may also be used as carrier proteins.

After the capsular polysaccharide is conjugated to the carrier protein, the polysaccharide-protein conjugate (enriched with respect to the amount of polysaccharide-protein conjugate) is purified by a variety of techniques. These include concentration/diafiltration operations, precipitation/elution, column chromatography and depth filtration (depth filtration). See the examples below.

After purification of each complex carbohydrate, they are mixed to formulate the immunogenic composition of the invention, which can be used as a vaccine. The formulation of the immunogenic compositions of the invention can be accomplished using methods well known in the art. For example, 13 respective pneumococcal conjugates can be formulated with a physiologically acceptable carrier to prepare a composition. Examples of such carriers include, but are not limited to, water, buffered saline, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol), and glucose solutions.

In some embodiments, the immunogenic composition will comprise one or more adjuvants. As defined herein, an "adjuvant" is a substance used to enhance the immunogenicity of the immunogenic composition of the invention. Thus, adjuvants are typically administered to boost the immune response and are well known to the skilled artisan. Suitable adjuvants for enhancing the effectiveness of the composition include, but are not limited to:

(1) Aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, and the like;

(2) Oil-in-water emulsion formulations (with or without other specific immunostimulants, such as muramyl peptides (defined below) or bacterial cell wall components), e.g.,

(a) MF59 (PCT publication WO 90/14837) containing 5% squalene, 0.5% Tween 80, and 0.5% span 85 (optionally containing varying amounts of MTP-PE (see below, although not required), formulated into submicron particles using a microfluidizer such as type 110Y microfluidizer (Microfluidics, newton, mass.),

(b) SAF, 10% squalene, 0.4% Tween 80,5% polymer L121 of pluronic blocks, and thr-MDP (see below), microfluidization to submicron emulsion or vortexing to produce emulsion of larger particle size, and

(c)Ribi ^TM adjuvant System (RAS), (Corixa, hamilton, MT), containing 2% squalene, 0.2% Tween 80, and 3-O-deacylated monophosphoryl lipid A (MPL) selected from those described in U.S. Pat. No.4,912,094 ^TM ) Of (a), trehalose Dimycolate (TDM), and a Cell Wall Skeleton (CWS), preferably MPL + CWS (Detox) ^TM )；

(3) Saponin adjuvant such as Quil A or STIMULON can be used ^TM QS-21 (antibiotics, framingham, MA) (U.S. Pat. No. 5,057,540) or particles derived therefrom, such as ISCOMs (immune stimulating complexes);

(4) Bacterial lipopolysaccharides, synthetic lipid a analogs such as aminoalkyl glucosamine phosphate compounds (AGP), or derivatives or analogs thereof, which are available from Corixa and described in U.S. patent No. 6,113,918; one such AGP is 2- [ (R) -3-tetradecanoyloxytetradecanoylamino ] ethyl 2-deoxy-4-O-phosphono-3-O- [ (R) -3-tetradecanoyloxytetradecanoyl ] -2- [ (R) -3-tetradecanoyloxytetradecanoylamino ] -b-D-glucopyranoside, also known as 529 (formerly RC 529), formulated in aqueous form or as a stable emulsion, a synthetic polynucleotide such as an oligonucleotide containing a CpG motif (U.S. Pat. No. 6,207,646);

(5) Cytokines such as interleukins (e.g., IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, IL-15, IL-18, etc.), interferons (e.g., gamma interferon), granulocyte macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF), tumor Necrosis Factor (TNF), co-stimulatory molecules B7-1 and B7-2, etc.;

(6) Detoxified mutants of bacterial ADP-ribosylating toxins, such as wild-type or mutant Cholera Toxin (CT), e.g. in which the glutamic acid at amino acid position 29 is replaced by another amino acid, preferably histidine (according to published International patent application No. WO 00/18434 (see also WO02/098368 and WO 02/098369)), pertussis Toxin (PT), or E.coli heat-Labile Toxin (LT), in particular LT-K63, LT-R72, CT-S109, PT-K9/G129 (see e.g. WO 93/13302 and WO 92/19265), and

(7) Other substances that act as immunostimulants to enhance the effectiveness of the composition.

Muramyl peptides include, but are not limited to, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-orthopolylocyl-L-alanine-2- (1 '-2' dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy) -ethylamine (MTP-PE), and the like.

The vaccine compositions of the present invention may be used to protect or treat persons susceptible to pneumococcal infection by administering the vaccine by systemic or mucosal routes. These administrations may include injections by intramuscular, intraperitoneal, intradermal or subcutaneous routes, or administration to the oral/digestive, respiratory or genitourinary tracts via the mucosa. In one embodiment, intranasal administration is used to treat pneumonia or otitis media (as nasopharyngeal carriage by pneumococci can be more effectively prevented, thereby reducing infection at its earliest stages).

The amount of conjugate in each vaccine dose is selected as the amount that induces immune protection without significant adverse effects. Such amounts may vary depending on the pneumococcal serotype. Typically, each dose will contain from 0.1 to 100. Mu.g of polysaccharide, especially from 0.1 to 10. Mu.g, more especially from 1 to 5. Mu.g.

The optimal amounts of the components of a particular vaccine are determined by standard studies involving observing an appropriate immune response in a subject. After the initial vaccination, the subject may receive one or several booster immunizations at sufficient intervals.

In a particular embodiment of the invention, the 13vPnC vaccines are each conjugated to CRM ₁₉₇ Can be administered to a patient in need thereof, and is a sterile liquid formulation of pneumococcal capsular polysaccharides of serotypes 1,3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F of (a). Every 0.5mL dose was formulated to contain: 2 μ g of each saccharide, except 4 μ g of 6B; about 29 μ g CRM ₁₉₇ A carrier protein; 0.125mg elemental aluminum (0.5 mg aluminum phosphate) adjuvant; and sodium chloride and sodium succinate buffers as excipients. The liquid was filled into a single dose syringe without preservative. ShakingThereafter, the vaccine is homogeneous and a white suspension is available for intramuscular administration.

The selection of dose levels for the 13vPnC vaccine was similar to the marketed 7vPnC vaccine (Prevnar). A2 μ g sugar dose level was chosen for all serotypes, but 4 μ g per dose for 6B. The 7vPnC vaccine has shown desirable safety, immunogenicity and efficacy against IPD at 2 μ g sugar dose levels for serotypes 4, 9V, 14, 18C, 19F and 23F and at 4 μ g dose levels for 6B.

The immunization protocol may follow the protocol specified for the 7vPnC vaccine. For example, conventional regimens for infants and toddlers with streptococcus pneumoniae suffering from invasive disease due to serotypes included in the 13vPnC vaccine are 2, 4,6 and 12-15 months of age. The compositions of the present invention are also suitable for use by older children, adolescents and adults.

The compositions of the invention may further comprise one or more additional antigens for use against otitis media caused by other bacterial infections. Such bacteria include atypical Haemophilus influenzae (Haemophilus influenza), moraxella catarrhalis (formerly known as Branhamella catarrhalis) and Alliococcus otidis.

Examples of Haemophilus influenzae antigens suitable for inclusion include the P4 protein, also known as protein "e" (U.S. Pat. No. 5,601,831; international patent application WO 03/078453), the P6 protein, also known as PAL or PBOMP-1 protein (U.S. Pat. No. 5,110,908; international patent application WO 0100790), the P5 protein (U.S. reissue patent No. 37,741), haemophilus adhesion and penetration proteins (U.S. Pat. Nos. 6,245,337 and 6,676,948), the LKP tip adhesin protein (U.S. Pat. No. 5,643,725) and the NucA protein (U.S. Pat. No. 6,221,365).

Examples of moraxella catarrhalis antigens suitable for inclusion include the UspA2 protein (U.S. patent No. 5,552,146,6,310,190), the CD protein (U.S. patent No. 5,725,862), the E protein (U.S. patent No. 5,948,412) and the 74 kilodalton outer membrane protein (U.S. patent No. 6,899,885).

Examples of Alloiococcus otitidis antigens suitable for inclusion include those identified in international patent application WO 03/048304.

The compositions of the present invention may also include one or more proteins from streptococcus pneumoniae. Examples of streptococcus pneumoniae proteins suitable for inclusion include those identified in international patent application WO02/083855 and those described in international patent application WO 02/053761.

The compositions of the invention may further comprise one or more proteins from type B meningitidis naphthalene coccus (Neisseria meningitidis). Examples of meningococcal type B proteins suitable for inclusion include those identified in International patent applications WO03/063766, WO2004/094596, WO01/85772, WO02/16612 and WO 01/87939.

The above disclosure generally describes the present invention. The present invention will be more fully understood from the following specific examples. These examples are for illustrative purposes only and are not intended to limit the scope of the present invention.

Examples

Example 1

Preparation of Streptococcus pneumoniae capsular polysaccharide serotype 1

Preparation of Master and working cell banks

Streptococcus pneumoniae serotype 1 was obtained from American type culture Collection ATCC strain 6301. Several generations of seed stocks were produced in order to enlarge the strain and to remove animal-derived components (F1, F3 and F3 generations). Two additional generations of seed stock were produced. The first additional generation was obtained from the F3 bottle and the subsequent generation was obtained from the first additional generation bottle. Seed bottles were cryopreserved (< -70 ℃) with synthetic glycerol as the refrigerant. In addition to the frozen vials, lyophilized vials were prepared from the F4 generation. To prepare the cell banks, all cultures were grown in soy-based medium. Prior to freezing, the cells are concentrated by centrifugation, the spent medium is removed, and the cell pellet is resuspended in fresh medium containing a cryopreservative such as synthetic glycerol.

Fermentation and harvesting

Cultures from the working cell bank were used to inoculate seed flasks containing soy-based media. The bottles were incubated at 36 ± 2 ℃ without stirring until growth requirements were met. Seed bottles were used to inoculate seed fermentors containing soy-based media. A pH of about 7.0 was maintained with sterile sodium carbonate solution. After the target optical density is reached, the seed fermentor is used to inoculate a production fermentor containing a soy-based medium. The pH was maintained with sterile sodium carbonate solution. The fermentation is terminated after the growth has stopped or after the working volume of the fermenter has been reached. An appropriate amount of sterile 12% sodium deoxycholate was added to the culture to lyse the bacterial cells and release the cell-bound polysaccharide. After lysis, the fermentor contents were cooled. The pH of the lysed broth was adjusted to about pH 6.6 with acetic acid. The lysate was clarified by continuous flow centrifugation followed by depth filtration and 0.45 μm microfiltration.

In an alternative process, a fermentation pH of about 7.0 is maintained with 3N NaOH. After the target optical density is reached, the seed fermentor is used to inoculate a production fermentor containing a soy-based medium. The pH was maintained with 3N NaOH. The fermentation is terminated after the growth has stopped or after the working volume of the fermenter has been reached. An appropriate amount of sterile 12% sodium deoxycholate was added to the culture to give a concentration of 0.12% in the culture broth to lyse the bacterial cells and release the cell-bound polysaccharide. After lysis, the fermentor contents were held for a time interval of 8 to 24 hours with stirring at a temperature of 7 ℃ to 13 ℃ to ensure that complete cell lysis and polysaccharide release had occurred. Agitation during this hold period prevents the lysis deposits from settling on the fermentor walls and pH probe, allowing the pH probe integrity to be maintained. Next, the pH of the lysed cell culture broth was adjusted to about pH5.0 with 50% acetic acid. After a time interval of 12 to 24 hours at a temperature of 15 ℃ to 25 ℃ without stirring, a significant portion of the previously dissolved protein precipitates out of solution as a solid precipitate with little loss or degradation of the polysaccharide, which remains in solution. The solution with the precipitate was then clarified by continuous flow centrifugation followed by depth filtration and 0.45 μm microfiltration.

Purification of

The purification of pneumococcal polysaccharides consists of several concentration/diafiltration operations, precipitation/elution, column chromatography and depth filtration steps. All steps were performed at room temperature unless otherwise indicated.

Clarified broth from the fermentor culture of streptococcus pneumoniae serotype 1 was concentrated and diafiltered with a 100kDa MWCO (kilodalton molecular weight cut-off) filter. Diafiltration was done at neutral pH using sodium phosphate buffer. Diafiltration removes low molecular weight media components from higher molecular weight biopolymers such as nucleic acids, proteins and polysaccharides.

Precipitating the polysaccharide from the concentrated and diafiltered solution by adding cetyltrimethylammonium bromide (HB) from the stock solution to obtain a final concentration of 1% HB (w/v). The polysaccharide/HB precipitate was captured on a depth filter and the filtrate was discarded. The polysaccharide precipitate was redissolved and eluted by recirculating the sodium chloride solution through a depth filter containing the precipitate. The filter was then rinsed with additional sodium chloride solution.

Sodium iodide (NaI) from a NaI stock solution was added to the polysaccharide solution to a final concentration of 0.5% to precipitate HB. The precipitate was removed by depth filtration. The filtrate contains the target polysaccharide. The precipitation vessel and filter were rinsed with NaCI/NaI solution and the rinse was combined with the partially purified polysaccharide solution. The filter was discarded. The polysaccharide was then filtered through a 0.2 μm filter.

The polysaccharide solution was concentrated on a 30kDa MWCO ultrafiltration membrane and diafiltered with sodium chloride solution.

The partially purified polysaccharide solution was further purified by filtration through a depth filter impregnated with activated carbon. After filtration, the carbon filter was rinsed with sodium chloride solution. The rinse was combined with the polysaccharide solution, which was then filtered through a 0.2 μm filter.

The polysaccharide solution was concentrated on a 30kDa MWCO ultrafiltration membrane and adjusted with 1M sodium phosphate buffer to achieve a final concentration of 0.025M sodium phosphate. The pH was checked and adjusted to 7.0. + -. 0.2.

A ceramic Hydroxyapatite (HA) column was equilibrated with sodium phosphate buffer containing sodium chloride to obtain a suitable conductivity (< 15 μ S). The polysaccharide solution is then loaded onto the column. Under these conditions, the impurities bind to the resin and the polysaccharide is recovered from the permeate of the column. The polysaccharide solution was filtered through 0.2 μm in-line filters located before and after the column.

The polysaccharide solution was concentrated using a 30kDa MWCO filter. The concentrate was then diafiltered with Water for Injection (WFI).

The diafiltered polysaccharide solution was filtered through a 0.2 μm filter into a polypropylene bottle. Samples were taken for release testing and the purified polysaccharides were cryopreserved at-25 ° ± 5 ℃.

Characterization of

The 1H-NMR data are consistent with the chemical structure by assignment of signals to protons assigned to the polysaccharide molecules. The 1H-NMR spectrum shows a series of well resolved signals (protons from methyl groups) which are used to quantify the O-ethyl functions in the polysaccharide.

The identity of the monovalent polysaccharide was confirmed by countercurrent immunoelectrophoresis using specific antisera.

High performance gel filtration chromatography coupled with refractive index and multi-angle laser light scattering (MALLS) detectors was used in conjunction with sample concentration to calculate molecular weight.

The relative molecular size distribution of the polysaccharides was delineated by size exclusion chromatography media (CL-4B).

Example 2

Preparation of serotype 1 pneumococcal saccharide-CRM ₁₉₇ Conjugate

Activation and conjugation

The containers of purified polysaccharide were thawed and combined in the reaction vessel. 0.2M sodium carbonate pH 9.0 was added to the vessel for partial deacetylation (hydrolysis) at 50 ℃ for 3 hours. The reaction was cooled to 20 ℃ and neutralized with 0.2M acetic acid. By incubation at 2-8 deg.C, oxidation is carried out in the presence of sodium periodate and the mixture is stirred for 15-21 hours.

The activation reaction mixture was concentrated and diafiltered 10 times with 0.9% NaCl using a 30K MWCO membrane. The retentate was filtered through a 0.2 μm filter. The activated sugars were filled into 100mL glass lyophilization vials and roller frozen at-75 ℃ and lyophilized.

"roll-freezing" (Shell-freezing) is a method of preparing samples for lyophilization (freeze-drying). The flask was rolled automatically by motor-driven rollers in a chilled water bath containing alcohol and any other suitable liquid. A thin coating of frozen product uniformly around the inner "shell" of the vial allows for the safe handling of larger volumes of material during each freeze-drying run. These automated freezing units provide a simple and efficient method of pre-freezing many flasks at once, producing the desired coating on the inside, and providing sufficient surface area for efficient freeze-drying.

The vial of lyophilized material was returned to room temperature and resuspended in CRM at a sugar/protein ratio of 2:1 ₁₉₇ In solution. To the sugar/protein mixture was added 1M sodium phosphate buffer to a final 0.2M ionic strength and pH of 7.5, followed by sodium cyanoborohydride. The reaction was incubated at 23 ℃ for 18 hours, followed by another incubation at 37 ℃ for 72 hours. After cyanoborohydride incubation, the reaction mixture was diluted with cold brine, followed by the addition of 1M sodium carbonate to adjust the reaction mixture to pH 9.0. The unreacted aldehyde was quenched by the addition of sodium borohydride and incubation at 23 ℃ for 3-6 hours.

The reaction mixture was diluted 2-fold with brine and transferred to the retentate vessel through a 0.45-5 μm prefilter. The reaction mixture was diafiltered 30 times with 0.15M phosphate buffer (pH 6) and 20 times with brine. The retentate was filtered through a 0.2 μm filter.

The conjugate solution was diluted with 0.9% saline to a target of 0.5mg/mL and then sterile filtered in a Class100 fume hood into a Final Bulk Concentrate (FBC) vessel. The conjugate was stored at 2-8 ℃.

Characterization of

The relative molecular size distribution of the conjugates was delineated with size exclusion chromatography media (CL-4B).

The identity of the conjugate was confirmed by slot blot assay using specific antisera.

Sugar and protein concentrations were determined by uronic acid and Lowry assays, respectively. The ratio of saccharide to protein in the covalently bound conjugate complex was calculated by:

o-acetyl content was measured by the Hestrin method (Hestrin et. Al, j.biol.chem.1949,180, p.249). The ratio of O-acetyl concentration to total sugar concentration gives micromoles O-acetyl/mg sugar.

Example 3

Preparation of Streptococcus pneumoniae capsular polysaccharide serotype 3

Preparation of Master and working cell banks

Streptococcus pneumoniae serotype 3 was obtained from Robert Australian, inc. (University of Pennsylvania, philadelphia, pennsylvania). The cell bank system was prepared as described in example 1.

Fermentation and harvesting

Cultures from the working cell bank were used to inoculate seed flasks containing soy-based media. The bottles were incubated at 36 ± 2 ℃ without stirring until growth requirements were met. Seed flasks were inoculated into seed fermentors containing soy-based media. The pH was maintained at about 7.0 with sterile sodium carbonate solution. After the target optical density was reached, the seed fermentor was inoculated with an intermediate seed fermentor. After the target optical density is reached, the production fermentor is inoculated with an intermediate seed fermentor. The pH was maintained with sterile sodium carbonate solution. The fermentation was terminated after the working volume of the fermentor was reached. An appropriate amount of sterile 12% sodium deoxycholate was added to the culture to lyse the bacterial cells and release the cell-bound polysaccharide. After lysis, the fermentor contents were cooled. The pH of the lysed broth was adjusted to about pH 6.6 with acetic acid. Lysates were clarified by continuous flow centrifugation followed by depth filtration and 0.45 μm microfiltration.

Purification of

Clarified broth from the fermentor culture of streptococcus pneumoniae serotype 1 was concentrated and diafiltered with a 100kDa MWCO filter. Diafiltration was done at neutral pH using sodium phosphate buffer. Diafiltration removes low molecular weight media components from higher molecular weight biopolymers such as nucleic acids, proteins and polysaccharides.

Before the addition of cetyltrimethylammonium bromide (HB), a calculated volume of NaCl stock solution was added to the concentrated and diafiltered polysaccharide solution to give a final concentration of 0.25M NaCl. The polysaccharide was then precipitated by adding HB from the stock solution to give a final concentration of 1% HB (w/v). The polysaccharide/HB precipitate was captured on a depth filter and the filtrate was discarded. The polysaccharide precipitate was redissolved and eluted by recirculating the sodium chloride solution through a depth filter containing the precipitate. The filter was then rinsed with additional sodium chloride solution.

The partially purified polysaccharide solution was further purified by filtration through a depth filter impregnated with activated carbon. After filtration, the carbon filter was rinsed with sodium chloride solution. The rinse was combined with the polysaccharide solution and then filtered through a 0.2 μm filter.

The ceramic Hydroxyapatite (HA) column was equilibrated with sodium phosphate buffer containing sodium chloride to obtain the appropriate conductivity (15 μ S). The polysaccharide solution is then loaded onto the column. Under these conditions, the impurities bind to the resin and the polysaccharide is recovered from the permeate of the column. The polysaccharide was washed through the column with buffer and filtered through a 0.2 μm filter.

The polysaccharide solution was concentrated using a 30kDa MWCO filter. The concentrate was then diafiltered with WFI.

The diafiltered polysaccharide solution was filtered through a 0.2 μm filter into a stainless steel vessel. Samples were taken for release testing and the purified polysaccharides were cryopreserved at-25 ° ± 5 ℃.

Characterization of

The 1H-NMR data are consistent with the chemical structure by assignment of signals to protons assigned to the polysaccharide molecules.

The relative molecular size distribution of the polysaccharides was characterized by size exclusion chromatography media (CL-4B).

Example 4

Serotype 3 pneumococcal saccharide-CRM ₁₉₇ Preparation of conjugates

Activation and conjugation

Containers of purified serotype 3 saccharide were thawed and combined in the reaction vessel. To this vessel, WFI and 2M acetic acid were added to a final concentration of 0.2M and 2mg/ml sugar. The temperature of the solution was raised to 85 ℃ for 1 hour to hydrolyze the polysaccharide. The reaction was cooled to 25 ℃ or less and 1M magnesium chloride was added to a final concentration of 0.1M. The oxidation was carried out by incubation at 23 ℃ for 16-24 hours in the presence of sodium periodate.

The activated reaction mixture was concentrated and diafiltered 10 times with WFI using a 100K MWCO membrane. The retentate was filtered through a 0.2- μm filter.

For formulation, 0.2M sodium phosphate (pH 7.0) was added to the activated sugar to a final concentration of 10mM and a pH of 6.0-6.5. CRM ₁₉₇ Carrier protein was mixed with sugar solution to 2g sugar/1 g CRM ₁₉₇ The ratio of (a) to (b). The combined sugar/protein solution was filled into a 100mL glass lyophilization flask with a target fill of 50mL, roller frozen at-75 ℃, and lyophilized.

The co-lyophilized sugar/protein material vial was allowed to return to room temperature and resuspended in 0.1M sodium phosphate buffer (pH 7.0) to a final sugar concentration of 20 mg/mL. The pH was adjusted to 6.5 and then 0.5 molar equivalents of sodium cyanoborohydride was added. The reaction was incubated at 37 ℃ for 48 hours. After cyanoborohydride incubation, the reaction mixture was diluted with cold 5mM succinate/0.9% saline buffer. The unreacted aldehyde was quenched by the addition of sodium borohydride and incubation at 23 ℃ for 3-6 hours. Transfer the reaction mixture through a 0.45-5 μm prefilter to a retentate vessel.

The reaction mixture was diafiltered 30 times with 0.1M phosphate buffer (pH 9), 20 times with 0.15M phosphate buffer (pH 6), and 20 times with 5mM succinate/0.9% saline. The retentate was filtered through a 0.2- μm filter.

The conjugate solution was diluted to 0.5mg/mL of the sugar target and then sterile filtered into FBC vessels in a Class100 fume hood. The conjugate was stored at 2-8 ℃.

Characterization of

Sugar and protein concentrations were determined by Anthrone and Lowry assays, respectively. The ratio of saccharide to protein in the covalently bound conjugate complex was obtained by the following calculation:

example 5

Preparation of Streptococcus pneumoniae capsular polysaccharide serotype 5

Streptococcus pneumoniae serotype 5 was obtained from Gerald Schiffman, state University of New York, brooklyn, new York. The cell bank system was prepared as described in example 1. Fermentation, harvesting, purification and characterization of the polysaccharide are described in example 1.

Alternative fermentation process

Cultures from working cell banks were used to inoculate cultures containing soy-based medium and 10mM sterile NaHCO ₃ Seed bottles of the solution. The bottles were incubated at 36 ℃. + -. 2 ℃ without stirring until growth requirements were met. Seed bottles were inoculated with a medium containing soy-based and 10mM sterile NaHCO ₃ Seed fermentor of the solution. The pH was maintained at about 7.0 with 3N NaOH. After the target optical density was reached, the seed fermentor was inoculated with a medium containing soy base with 10mM NaHCO ₃ Production fermentor of concentration. The pH was maintained with 3N NaOH. The fermentation is stopped after the growth is stopped or when the working volume of the fermentation tank is reached. Adding a suitable amount of sterile 12% sodium deoxycholate to the culture to give a concentration of 0.12% in the culture broth for lysis of bacterial cells and releaseCell-bound polysaccharides are released. After lysis, the fermentor contents were maintained at a temperature of 7 ℃ to 13 ℃ for a time interval of 8 to 24 hours with stirring to ensure that complete cell lysis and polysaccharide release had occurred. Agitation during this hold period prevents the lysis deposits from settling on the fermentor walls and pH probe, allowing the pH probe integrity to be maintained. The pH of the lysed cell culture broth was then adjusted to about pH4.5 with 50% acetic acid. After a time interval of 12 to 24 hours at a temperature of 15 ℃ to 25 ℃ without stirring, a significant portion of the previously dissolved protein precipitates out of solution as a solid precipitate with little loss or degradation of the polysaccharide, which remains in solution. The solution with the precipitate was then clarified by continuous flow centrifugation followed by depth filtration and 0.45 μm microfiltration.

Example 6

Preparation of serotype 5 pneumococcal saccharide-CRM ₁₉₇ Conjugates

Activation and conjugation

Containers of serotype 5 saccharide were thawed and combined in the reaction vessel. To this vessel was added 0.1M sodium acetate (pH 4.7), followed by oxidation by incubation at 23 ℃ for 16-22 hours in the presence of sodium periodate.

Reacting serotype 5 activated saccharide with CRM ₁₉₇ The ratio of 0.8. The combined sugar/protein solutions were filled into 100mL glass lyophilization vials (50 mL target fill) and roller frozen at-75 ℃ and co-lyophilized.

The vial of co-lyophilized material was allowed to return to room temperature and resuspended in 0.1M sodium phosphate (pH 7.5) and sodium cyanoborohydride was added. The reaction was incubated at 30 ℃ for 72 hours, followed by another addition of sodium cyanoborohydride and incubation at 30 ℃ for 20-28 hours.

After incubation with sodium cyanoborohydride, the reaction mixture was diluted 2-fold with brine and transferred through a 0.45-5 μm prefilter into a retentate vessel. The reaction mixture was diafiltered 30 times with 0.01M phosphate buffer (pH 8), 20 times with 0.15M phosphate buffer (pH 6), and 20 times with brine. The retentate was filtered through a 0.2 μm filter.

The conjugate was characterized as in example 2.

Example 7

Preparation of Streptococcus pneumoniae capsular polysaccharide serotype 6A

Streptococcus pneumoniae serotype 6A was obtained from Gerald Schiffman, ph.D. (State University of New York, brooklyn, new York). The cell bank system was prepared as described in example 1. Fermentation, harvest and purification of the polysaccharide see example 1, except that during purification, the 30kDa MWCO concentration step prior to the chromatography step is omitted.

Example 8

Preparation of serotype 6A pneumococcal saccharide-CRM ₁₉₇ Conjugates

Activation and conjugation

Serotype 6A polysaccharide is a high molecular weight polymer that must be reduced in size prior to oxidation. The vessels of serotype 6A saccharide were thawed and combined in the reaction vessel. 2M acetic acid was added to the vessel to a final concentration of 0.1M for hydrolysis at 60 ℃ for 1.5 hours. The reaction was cooled to 23 ℃ and neutralized by adjusting the reaction mixture to pH6 with 1m naoh. Oxidation was carried out by incubation at 23 ℃ for 14-22 hours in the presence of sodium periodate.

The activation reaction mixture was concentrated and diafiltered with WFI using a 100K MWCO membrane. The retentate was filtered through a 0.2 μm filter.

Serotype 6A was formulated with sucrose and filled into 100mL glass lyophilization vials (50 mL target fill) and roller frozen at-75 ℃ and lyophilized.

The vial of lyophilized material was returned to room temperature and resuspended in dimethyl sulfoxide (DMSO) at a sugar/protein ratio of 1:1. After addition of sodium cyanoborohydride, the reaction mixture was incubated at 23 ℃ for 18 hours. After incubation with sodium cyanoborohydride, the reaction mixture was diluted with cold brine. The unreacted aldehyde was quenched by addition of sodium borohydride by incubation at 23 ℃ for 3-20 hours.

The diluted reaction mixture was transferred through a 5 μm prefilter to a retentate vessel. The reaction mixture was diafiltered 10 times with 0.9% NaCl and 30 times with succinate buffered NaCl. The retentate was filtered through a 0.2 μm filter.

The conjugate was characterized as in example 2.

Example 9

Preparation of Streptococcus pneumoniae capsular polysaccharide serotype 7F

Streptococcus pneumoniae serotype 7F was obtained from Gerald Schiffman, state University of New York, brooklyn, new York. Preparation of the cell bank system and fermentation and harvesting of the polysaccharide are described in example 3. For alternative fermentation and harvesting methods, see the alternative methods described in example 1.

Purification of

Purification of streptococcus pneumoniae polysaccharides consists of several concentration/diafiltration operations, precipitation/elution, column chromatography and depth filtration steps. All steps were performed at room temperature unless otherwise indicated.

Clarified broth from the fermentor culture of streptococcus pneumoniae serotype 7F was concentrated and diafiltered with a 100kDa MWCO filter. Diafiltration was done at neutral pH using sodium phosphate buffer. Diafiltration removes low molecular weight media components from higher molecular weight biopolymers such as nucleic acids, proteins and polysaccharides.

Serotype 7F did not precipitate with HB. Instead, the impurities are precipitated from the concentrated and diafiltered solution by adding HB from stock solution to 1% of the final concentration of HB. The precipitate was captured on a depth filter and the filter was discarded. The filtrate contains polysaccharides.

Sodium iodide (NaI) from a NaI stock solution was added to the polysaccharide solution to a final concentration of 0.5% to precipitate HB. The precipitate was removed by depth filtration. The filtrate contains the target polysaccharide. The precipitation vessel and filter were rinsed with NaCI/NaI solution and the rinsing combined with partially purified polysaccharide solution. The filter was discarded. The polysaccharide was then filtered through a 0.2 μm filter.

The diafiltered polysaccharide solution was filtered through a 0.2 μm filter into a stainless steel vessel. Samples were taken for release testing and the purified polysaccharides were cryopreserved at 2 ℃ to 8 ℃.

The polysaccharide was characterized as in example 3.

Example 10

Preparation of serotype 7F pneumococcal saccharide-CRM ₁₉₇ Conjugates

Activation and conjugation

The oxidation was carried out by incubation at 23 ℃ for 16-24 hours in the presence of sodium periodate.

The activated reaction mixture was concentrated and diafiltered 10 times with 10mM NaOAc, pH4.5, using a 100K MWCO membrane. The retentate was filtered through a 0.2 μm filter.

Serotype 7F was filled into 100mL glass lyophilization vials (50 mL target fill), roller frozen at-75 ℃ and lyophilized.

Lyophilized serotypes 7F and CRM ₁₉₇ The bottle of (a) was brought to room temperature and resuspended in DMSO at a sugar/protein ratio of 1.5. After addition of sodium cyanoborohydride, the reaction was incubated for 8-10 hours at 23 ℃. Tong (Chinese character of 'tong')The unreacted aldehyde was quenched by the addition of sodium borohydride and incubation at 23 ℃ for 16 hours.

The reaction mixture was diluted 10-fold with cold brine and transferred to the retentate vessel through a 5 μm prefilter. The reaction mixture was diafiltered 10 times with 0.9% brine and 30 times with succinic acid buffered brine. The retentate was filtered through a 0.2 μm filter.

The conjugate solution was diluted with 0.9% saline to 0.5mg/mL of the sugar target and then aseptically filtered into FBC vessels in a Class100 fume hood. The conjugate was stored at 2-8 ℃.

The conjugate was characterized as in example 4.

Example 11 preparation of Streptococcus pneumoniae capsular polysaccharide serotype 19A

Streptococcus pneumoniae serotype 19A was obtained from Gerald Schiffman, ph.D. (State University of New York, brooklyn, new York). For preparation of cell bank systems see example 1. Fermentation, harvesting and purification of the polysaccharide are described in example 7. See example 3 for characterization.

Example 12

Serotype 19A pneumococcal saccharide-CRM ₁₉₇ Preparation of conjugates

Activation and conjugation

Containers of serotype 19A saccharide were thawed and combined in the reaction vessel. Sodium acetate was added to 10mM (pH 5.0) and oxidation was carried out by incubation at 23 ℃ for 16-24 hours in the presence of sodium periodate.

The activation reaction mixture was concentrated and diafiltered 10 times with 10mM acetate, pH5.0, using a 100K MWCO membrane. The retentate was filtered through a 0.2 μm filter.

Formulation of activated sugar with sucrose followed by addition of CRM ₁₉₇ . Serotype 19A activated saccharide and CRM ₁₉₇ The mixture (0.8.

The vial of lyophilized material was returned to room temperature and resuspended in DMSO. Sodium cyanoborohydride (100 mg/ml) was added to the sugar/protein mixture. The reaction was incubated at 23 ℃ for 15 hours. After cyanoborohydride incubation, unreacted aldehyde was quenched by addition of sodium borohydride, incubation at 23 ℃ for 3-20 hours.

The reaction mixture was diluted 10-fold with cold brine and transferred through a 5 μm prefilter into a retentate vessel. The reaction mixture was diafiltered 10 times with 0.9% NaCl, 0.45 μm filtered, and diafiltered 30 times with 5mM succinate/0.9% NaCl buffer, pH6. The retentate was filtered through a 0.2 μm filter.

The conjugate solution was diluted to 0.5mg/mL target with 5mM succinate/0.9% saline and then sterile filtered into FBC vessels in a Class100 fume hood. The conjugate was stored at 2-8 ℃.

The conjugate was characterized as in example 4.

Example 13

Preparation of Streptococcus pneumoniae capsular polysaccharide serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F

Preparation of Streptococcus pneumoniae seed cultures

Streptococcus pneumoniae serotypes 4, 6B, 9V, 18C, 19F and 23F were obtained from the Gerald Schiffman doctor (State University of New York, brooklyn, new York). Streptococcus pneumoniae serotype 14 was obtained from ATCC strain 6314.

A vial of each desired serotype of streptococcus pneumoniae was used separately to start the fermentation batch. Two flasks containing soy-based medium and phenol red were adjusted to a pH range of 7.4. + -. 0.2 with sodium carbonate, and then the required volume of 50% glucose/1% magnesium sulfate solution was added to the flask. Two bottles were inoculated with different amounts of seeds. The bottles were incubated at 36 ° ± 2 ℃ until the medium turned yellow. After incubation, samples were removed from each vial and tested for Optical Density (OD) (0.3 to 0.9) and pH (4.6 to 5.5). One of the two bottles was selected for inoculation of the seed fermentor.

The soy-based medium was transferred to a seed fermentor and sterilized. Then a volume of 50% glucose/1% magnesium sulfate solution was added to the fermentor. The pH of the seed fermentor was monitored and controlled (pH 6.7 to 7.4) and stirred. The temperature was maintained at 36 ℃. + -. 2 ℃. The seed inoculum (bottle) was aseptically connected to the seed fermentor and transferred. The fermentor was kept under pH control and samples were taken periodically and tested for OD and pH. When the desired OD 0.5 was reached at 600nm, the intermediate fermentor was inoculated with the fermentation broth from the seed fermentor.

The soy-based medium was transferred to an intermediate fermentor and sterilized. Then a volume of 50% glucose/1% magnesium sulfate solution was added to the fermentor. The pH of the intermediate fermentor was monitored and controlled (pH 6.7 to 7.4) and stirred. The temperature was maintained at 36 ℃. + -. 2 ℃. The contents of the seed fermentor were transferred to an intermediate fermentor. The fermentor was kept under pH control and samples were taken periodically and tested for OD and pH. When the desired OD 0.5 was reached at 600nm, the production fermenter was inoculated with the fermentation broth from the intermediate fermenter.

The soy-based medium was transferred to the production fermentor and sterilized. Then a volume of 50% glucose/1% magnesium sulfate solution was added to the fermentor. The pH of the production fermentor was monitored and controlled (pH 6.7 to 7.4) and stirred. The temperature was maintained at 36 ℃. + -. 2 ℃. The fermentor was kept under pH control and samples were periodically taken and tested for OD and pH until fermentation was complete.

Adding sodium deoxycholate to the fermentor to a final concentration of about 0.12% w/v. The cultures were mixed for a minimum of 30 minutes and the temperature adjustment point was lowered by 10 ℃. After overnight culture and confirmation of inactivation, the pH of the culture was adjusted to 6.4 to 6.8 with 50% acetic acid, if necessary. The temperature of the fermentor was raised to 20 ° ± 5 ℃ and the contents transferred to a clarification holding tank.

The contents of the holding tank (retaining the cell debris) were clarified by centrifugation at a flow rate of 25 to 600 liters per hour (except for serotype 4, where the cell debris was discarded and the flow rate was raised to 25 to 250 liters/hour). Samples of the supernatant were removed and tested for OD. The desired OD during centrifugation is ≦ 0.15.

Initially, the supernatant was recirculated through the depth filter device until an OD of 0.05 ± 0.03 was achieved. The supernatant was then passed through a depth filter device and through a 0.45 μm filter membrane to filter the filtrate holding tank.

The product was then transferred through a closed tube to a purification zone for disposal.

All the above operations (centrifugation, filtration and transfer) are carried out at between 10 ℃ and 30 ℃.

For alternative fermentation and harvesting methods for serotypes 4 and 6B, see the alternative methods described in example 1.

Purification of

Purification of each streptococcus pneumoniae polysaccharide consists of several concentration/diafiltration operations, precipitation/elution, column chromatography and depth filtration steps. All steps were performed at room temperature unless otherwise indicated.

Clarified broth from a fermentor culture of the desired streptococcus pneumoniae serotype was concentrated and diafiltered with a 100kDa MWCO filter. Diafiltration was done using sodium phosphate buffer at pH < 9.0. Diafiltration removes low molecular weight media components from higher molecular weight biopolymers such as nucleic acids, proteins and polysaccharides.

The polysaccharide was precipitated from the concentrated and diafiltered solution by adding HB from the stock solution to obtain a final concentration of 1-HB (w/v) (except serotype 23F, which had a final concentration of 2.5%). The polysaccharide/HB precipitate was captured on the depth filter and the filtrate was discarded (note: serotype 14 did not precipitate; thus the filtrate was retained). The polysaccharide precipitate was redissolved and eluted by recirculating the sodium chloride solution through a depth filter containing the precipitate. The filter was then rinsed with additional sodium chloride solution.

Sodium iodide (NaI) from a NaI stock solution was added to the polysaccharide solution to a final concentration of 0.5% to precipitate HB (except serotype 6B, which had a final concentration of 0.25%). The precipitate was removed by depth filtration. The filtrate contains the target polysaccharide. The filter was discarded. The polysaccharide was then filtered through a 0.2 μm filter.

The polysaccharide solution was concentrated on a 30kDa MWCO ultrafiltration membrane and the filter was rinsed with sodium chloride solution. The pH was checked and adjusted to 7.0. + -. 0.3.

The ceramic Hydroxyapatite (HA) column was equilibrated with sodium phosphate buffer containing sodium chloride until pH 7.0 ± 0.3 and conductivity 26 ± 4 μ S. The polysaccharide solution is then loaded onto the column. Under these conditions, the impurities bind to the resin and the polysaccharide is recovered from the permeate of the column. The polysaccharide solution was filtered through a 0.2 μm filter.

The polysaccharide solution was concentrated using a 30kDa MWCO filter. The concentrate was then diafiltered with WFI until conductivity <15 μ S.

The diafiltered polysaccharide solution was filtered through a 0.2 μm filter into a bulk container (bulk container) and stored at 2-8 ℃.

Example 14

Preparation of pneumococcal saccharide-CRM for serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F ₁₉₇ Conjugates

Activation method

Different serotype saccharides follow different routes for activation (hydrolysis or not before activation) and conjugation (aqueous or DMSO reactions), as described in this example.

Transferring the polysaccharide from the main vessel to a reactor vessel. The polysaccharide was then diluted with WFI and sodium phosphate to a final concentration range of 1.6-2.4 mg/mL.

Step 1

For serotypes 6B, 9V, 14, 19F, and 23F, the pH was adjusted to pH 6.0 ± 0.3.

For serotype 4, hydrochloric acid (0.01M final acid concentration) was added and incubated at 45 ° ± 2 ℃ for 25-35 minutes. The hydrolysis was stopped by cooling to 21-25 ℃ and adding 1M sodium phosphate to the target pH 6.7. + -. 0.2. In-process testing was performed to confirm the appropriate level of depyruvylation.

For serotype 18C, glacial acetic acid (0.2M final acid concentration) was added and the solution was incubated at 94 ° ± 2 ℃ for 205-215 minutes. The temperature was then lowered to 21-25 ℃ and 1-2M sodium phosphate was added to the target pH of 6.8. + -. 0.2.

Step 2: periodic acid reaction

The total sugar content (except serotype 4) was used to determine the molar equivalent of sodium periodate required for pneumococcal sugar activation. For serotype 4, a ratio of 0.8-1.2 moles of sodium periodate per mole of saccharide was used. With thorough mixing, the oxidation reaction was allowed to proceed at 21-25 ℃ for 16 to 20 hours for all serotypes except 19F, and a temperature of ≦ 15 ℃ for 19F.

And step 3: ultrafiltration

The oxidized saccharide was concentrated and diafiltered on a 100kDa MWCO ultrafiltration membrane (5 kDa ultrafiltration membrane for 18C) with WFI (0.01M sodium phosphate buffer pH 6.0 for serotype 19F). The permeate was discarded and the retentate was filtered through a 0.22 μm filter.

And 4, step 4: freeze-drying

For serotypes 4, 9V and 14, concentrated sugars were combined with CRM ₁₉₇ Mixing carrier proteins, placing into a glass bottle, rolling, freezing, and storing at-65 deg.C or below. Freeze-dried freeze-concentrated saccharide-CRM ₁₉₇ And stored at-25 ° ± 5 ℃.

For serotypes 6B, 19F, and 23F, sucrose was added in a specific amount calculated to achieve a sucrose concentration of 5% ± 3% in the conjugation reaction mixture. Serotype 18C did not require sucrose addition. Then the concentrated sugar is filled into a glass bottle, rolled and frozen and stored at-65 ℃. The concentrated sugar was lyophilized and stored at-25 ° ± 5 ℃.

Conjugation process

Two conjugation methods were used: aqueous conjugation was used for serotypes 4, 9V, 14 and 18c, dmso conjugation was used for serotypes 6B, 19F and 23F.

Aqueous conjugation

Step 1: dissolution

Thawing lyophilized activated saccharide-CRM for serotypes 4, 9V, and 14 ₁₉₇ The mixture was equilibrated at room temperature. The lyophilized activated sugar-CRM was then reconstituted with 0.1M sodium phosphate buffer at the specified ratio ₁₉₇ ：

1L buffer per 16-24g saccharide for serotypes 4 and 9V

For serotype 14, 1L buffer per 6-10g saccharide

For serotype 9V, the reaction mixture was incubated at 37 ° ± 2 ℃ until complete solubilization, and for serotypes 4 and 14, the reaction mixture was incubated at 23 ° ± 20 ℃ until complete solubilization.

For serotype 18C, in CRM ₁₉₇ Per 1LCRM in a solution of 1M disodium hydrogen phosphate ₁₉₇ 0.11L sodium phosphate solutionReconstituting the lyophilized saccharide. The reaction mixture (8-12 g/L sugar concentration) was incubated at 23 ° ± 2 ℃ until complete dissolution.

The pH is monitored at this stage as an in-process control.

Step 2: conjugation reactions

For serotypes 4 and 9V, the conjugation reaction was initiated by adding a solution of sodium cyanoborohydride (100 mg/mL) to achieve 1.0-1.4 moles of sodium cyanoborohydride per mole of saccharide. The reaction mixture was incubated at 37 ° ± 2 ℃ for 44-52 hours. The temperature was then reduced to 23 ° ± 2 ℃ and 0.9% sodium chloride was added to the reactor. Sodium borohydride solution (100 mg/mL) was added to achieve 1.8-2.2 molar equivalents of sodium borohydride per mole of sugar. The mixture was incubated at 23 ° ± 2 ℃ for 3-6 hours. The mixture was diluted with 0.9% sodium chloride and the reactor was flushed. The diluted conjugate mixture was filtered into a storage container using a 1.2 μm prefilter.

For serotypes 14 and 18C, the conjugation reaction was initiated by adding a solution of sodium cyanoborohydride (100 mg/mL) to achieve 1.0-1.4 moles of sodium cyanoborohydride per mole of saccharide. The reaction mixture was incubated at 23 ° ± 2 ℃ for 12-24 hours. The temperature was then raised to 37 ° ± 2 ℃ and the reaction incubated for 72-96 hours. The temperature was then reduced to 23 ° ± 2 ℃ and 0.9% sodium chloride was added to the reactor. Sodium borohydride solution (100 mg/mL) was added to achieve 1.8-2.2 molar equivalents of sodium borohydride per mole of sugar. The mixture was incubated at 23 ° ± 2 ℃ for 3-6 hours. The mixture was diluted with 0.9% sodium chloride and the reactor was flushed. The diluted conjugate mixture was filtered into a storage container using a 1.2 μm prefilter.

And step 3: ultrafiltration of 100kDa

The diluted conjugate mixture was concentrated and diafiltered on a 100kDa MWCO ultrafiltration membrane using a minimum of 15 volumes (serotype 4) or 40 volumes (serotypes 9V, 14 and 18C) of 0.9% sodium chloride.

The permeate was discarded.

For serotype 4, the retentate was filtered through a 0.45 μm filter.

During this step, the process control (sugar content) is carried out.

And 4, step 4: HA column purification

This step was performed only for serotype 4 conjugates.

The HA column was first neutralized with 0.5M sodium phosphate buffer (pH 7.0. + -. 0.3) and then equilibrated with 0.9% sodium chloride. The filtered retentate (serotype 4) was applied to the column at a flow rate of 1.0L/min. The column was washed with 0.9% sodium chloride at a flow rate of 2.0L/min or less. Then eluting the product with 0.5M sodium phosphate buffer solution at a flow rate of less than or equal to 2.0L/min.

The HA fraction was then concentrated and diafiltered on a 100kDa MWCO membrane with a minimum of 20 volumes of 0.9% sodium chloride. The leachate is discarded.

And 5: filtration sterilization

The retentate after diafiltration of the 100kDa MWCO was filtered through a 0.22 μm filter. The filtered product was subjected to in-process control (sugar content, free protein, free sugar and cyanide). The filtered retentate is subjected to in-process control to determine if additional concentration, diafiltration, and/or dilution is required to meet the FBC target. These and additional tests were repeated with FBC samples.

If desired, the filtered conjugate was diluted with 0.9% sodium chloride to achieve a final concentration of less than 0.55 g/L. Sugar content, protein content and sugar: release test of protein ratio.

Finally, the conjugate (0.22 μm) was filtered and loaded into a 10L stainless steel canister at a typical amount of 2.64 g/canister. At this stage, yield, sugar content, protein content, pH, sugar to protein ratio and lysine content were performed as intra-process controls. Release tests (appearance, free protein, free sugar, endotoxin, molecular size determination, residual cyanide, sugar identity, CRM197 identity) were performed at this stage.

Conjugation in DMSO

Step I dissolution

Lyophilized activated glycoseroforms 6B, 19F, 23F and lyophilized CRM197 carrier protein were equilibrated at room temperature and reconstituted with DMSO. The dilution concentration is usually 2-3g of sugar (2-2.5 g of sugar) per liter of DMSO.

Step II conjugation reaction

Combining the activated saccharide with CRM ₁₉₇ Carrier protein at 23 ° ± 2 ℃ with 0.6g-1.0g sugar/gCRM ₁₉₇ (for serotypes 6B and 19F) or 1.2 to 1.8g sugar/g CRM ₁₉₇ (for serotype 23F) ratio ranges from 60-75 minutes.

The conjugation reaction was initiated by adding a solution of sodium cyanoborohydride (100 mg/ml) at a ratio of 0.8-1.2 molar equivalents of sodium cyanoborohydride to 1 mole of activated sugar. To the reaction mixture was added WIF to 1% (v/v) of the target and the mixture was incubated at 23 ° ± 2 ℃ for more than 40 hours.

To the reaction was added sodium borohydride solution, 100mg/mL (typically 1.8-2.2 molar equivalents of sodium borohydride per mole of activated sugar) and WFI (goal 5%v/v) and the mixture was incubated at 23 ° ± 2 ℃ for 3-6 hours.

This step reduces any unreacted aldehyde on the sugar. The reaction mixture was then transferred to a dilution tank containing 0.9% sodium chloride at <15 ℃.

Step III:100kDa ultrafiltration

The diluted conjugate mixture was filtered through a 1.2 μ M filter and concentrated and diafiltered on a 100kDa MWCO membrane with a minimum of 15 volumes of 0.9% sodium chloride (0.01M sodium phosphate/0.05M NaCl buffer for serotype 23F). The permeate was discarded. The retentate was filtered through a 0.45 μm filter. During this phase an in-process sugar content sample was taken.

Step IV DEAE column purification

This procedure was performed only for serotype 23F.

The DEAE column was equilibrated with 0.01M sodium phosphate/0.05M sodium chloride buffer. The filtered retentate (serotype 23F) was loaded onto the column and washed with 0.01M sodium phosphate/0.05M sodium chloride buffer. The column was washed with 0.01M sodium phosphate/0.9% NaCl buffer. The product was then eluted with 0.01M sodium phosphate/0.5M sodium chloride buffer.

Step V100 kDa Ultrafiltration

The retentate from 6B and 19F was concentrated and diafiltered with at least 30 volumes of 0.9% sodium chloride. The permeate was discarded.

The eluate from serotype 23F was concentrated and diafiltered with a minimum of 20 volumes of 0.9% sodium chloride. The permeate was discarded.

Step VI: filtration sterilization

The retentate after diafiltration of the 100kDa MWCO was filtered through a 0.22 μm filter. The filtered product was subjected to in-process control (sugar content, free protein, free sugar, residual DMSO and residual cyanide). The filtered retentate is subjected to in-process control to determine if additional concentration, diafiltration, and/or dilution is required to meet FBC targets. These and additional tests were repeated with FBC samples.

Finally, the conjugate (0.22 μm) was filtered and loaded into a 10L stainless steel canister in an amount of 2.64 g/canister. At this stage, yield, sugar content, protein content, pH, sugar to protein ratio and lysine content were performed as intra-process controls. Release tests (appearance, free protein, free sugar, endotoxin, molecular sizing, residual cyanide, residual DMSO, sugar identity, CRM) were performed at this stage ₁₉₇ Identity).

Example 15

Formulation of multivalent pneumococcal conjugate vaccines

The final bulk concentrate of 13 conjugates contained 0.85% sodium chloride. 3. Bulk concentrates of types 6A, 7F and 19A also contained 5m sodium succinate buffer at pH 5.8. The required volume of bulk concentrate is calculated based on the batch volume and the bulk sugar concentration. After adding 80% of 0.85% sodium chloride (normal saline) and the required amount of succinate buffer to the pre-labeled formulation container, the bulk concentrate is added. The preparation was then sterilized by filtration through a 0.22 μm membrane into a second vessel using a Millipore Durapore membrane filter unit. The first vessel was washed with the remaining 20% of 0.85% sodium chloride and the vessel was passed through the same filter and collected into the second vessel. The formulated bulk is gently mixed during and after addition of bulk aluminum phosphate. Check the pH and, if necessary, adjust the pH. Storing the prepared bulk product at 2-8 deg.C.

The formulated bulk product was loaded into a type 1 borosilicate glass syringe obtained from Becton Dickinson. The turbidity of the vaccine was monitored periodically to ensure uniformity of the filling operation. The filled vaccine (final product) was stored at 2-8 ℃.

Example 16

Immunogenicity of 13-valent conjugate vaccines

To date, preclinical studies have been performed on the 13vPnC vaccine in rabbits. Studies # HT01-0021 and # HT01-0036 were designed to examine capsular Polysaccharide (PS) from Streptococcus pneumoniae independently of CRM ₁₉₇ Chemical conjugation and aluminum phosphate (AlPO) ₄ ) Effect of adjuvant on the immune response of the 13vPnC vaccine in rabbits. These effects were characterized by measuring serum IgG concentrations by antigen-specific ELISA and antibody function by opsonophagocytosis assay (OPA).

Study # HT01-0021

Study # HT01-0021 examination with AlPO ₄ The ability of the adjuvanted 13vPnC vaccine to elicit a vaccine serotype specific immune response. The pneumococcal serotypes represented in the 13vPnC vaccine include 1,3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. A second goal involves assessing the kinetics and duration of the antibody response. Use or non-use of AlPO with planned human clinical dose at week 0 and week 2 ₄ New Zealand White rabbits were immunized intramuscularly with each polysaccharide (2. Mu.g of each PS, but 4. Mu.g 6B) formulated (100. Mu.g/dose). Serum was collected at different time points. Serum specific IgG was measured by ELISA and functional activity was assessed by OPA.

Table 3 shows the Geometric Mean Titer (GMT) achieved in pooled serum samples after two doses of 13vPnC vaccine. Responses from week 4 to week 0 were compared with the ratio of IgG GMT. These data indicate the inclusion of AlPO in the 13vPnC formulation ₄ Results in higher levels of IgG antibodies than the same vaccine without adjuvant. Although when AlPO is included in the formulation ₄ The antibody response was greater, but these increases were not statistically significant.

Functional antibody responses were also assessed in rabbits following immunization with these two 13vPnC formulations (table 4). When compared to vaccine formulations with or without adjuvant at 13vPnC + AlPO ₄ Higher OPA GMT was observed in the vaccine treated group. In both groups, OPA titers were detected for all vaccine serotypes in pooled sera at week 4. OP measured at week 4 for most serotypesThe a titer is at least 4-fold higher than the OPA titer at week 0 (baseline).

The kinetic response to each 13vPnC vaccine serotype was evaluated from pooled sera from both treatment groups. IgG titers for each serotype were measured from blood drawn at week 0 and weeks 1,2, 3,4, 8, 12, 26, and 39, and then compared. Except for serotype 1, the antibody response in animals receiving the adjuvanted vaccine was better than that receiving the non-adjuvanted vaccine and peaked in the second week of the immunization schedule (data not shown).

In summary, the data indicate that the 13vPnC vaccine formulated with aluminium phosphate is immunogenic in rabbits, elicits substantial antibody responses against the pneumococcal capsular polysaccharide contained in the vaccine and that these responses are associated with functional activity. Using 13vPnC + AlPO ₄ The observed responses to the 7 core serotypes after immunization are consistent with the historical responses of rabbits to the 7 valent formulation.

TABLE 3 Rabbit IgG immune response (GMT) following immunization with two doses of 13-valent pneumococcal complex carbohydrate

GMT of pooled sera composed of equal volumes of sera from each rabbit in the group

b with no AlPO ₄ The treatment groups of (1) are statistically different (p = 0.022)

TABLE 4 Streptococcus pneumoniae OPA GMT in NZW rabbits pooled sera post immunization with 2 doses of 13 valent pneumococcal complex carbohydrate

A library consisting of equal volumes of serum from each rabbit in the treatment group (n = 12)

Study # HT01-0036

Study # HT01-0036 comparison with and without CRM ₁₉₇ Following immunization with the 13vPnC vaccine, the rabbits responded immunologically to the Polysaccharides (PS) contained in the vaccine species. At weeks 0 and 2, 2.2. Mu.g of eachNew Zealand White rabbits were immunized intramuscularly with PS (4.4. Mu.g 6B excluded). Animals received one of three vaccine formulations: (a) 13vPnC (PS directly conjugated to CRM) ₁₉₇ ) Either (b) 13vPnPS (free PS) or (c) 13vPnPS + CRM ₁₉₇ (free PS and CRM) ₁₉₇ Mixing). All vaccine formulations contained 125 μ g/dose of AlPO as adjuvant ₄ 。

Serotype specific immune responses to all vaccine formulations were assessed by IgG ELISA and functional antibodies were measured with complement-mediated OPA. The immune responses were compared between treatment groups.

Table 5 gives GMT data from week 4 bleeds analyzed with an antigen-specific IgG ELISA. Additional analysis showed the ratio of GMT values at week 4 and week 0. The data indicate that the conjugate vaccine formulation is more than free PS or free PS + CRM ₁₉₇ The vaccine elicited greater serum IgG titers. In addition to streptococcus pneumoniae type 14, the 13vPnC vaccine was able to induce functional antibodies in OPA against representative strains of streptococcus pneumoniae (table 6). CRM with 13vPnPS or 13vPnPS + ₁₉₇ After two immunizations with the vaccine, neither vaccine induced an OPA titer ≧ 8-fold at week 4 relative to week 0 for 10 of the 13 serotypes measured (Table 6).

Taken together, these results indicate that the conjugation ratio of 13-valent pneumococcal vaccine polysaccharide was either using free polysaccharide alone or with unconjugated CRM ₁₉₇ The mixed polysaccharide was seen to produce higher serum IgG titers and overall greater functional antibody activity.

TABLE 5 Rabbit IgG response to PnPS (GMT) measured by ELISA after immunization with 2 doses of 13 valent pneumococcal complex carbohydrate

TABLE 6 Streptococcus pneumoniae OPA titers from rabbit serum pool following immunization with 2 doses of 13 valent pneumococcal vaccine

a week 0 value for all groups

It should be understood that the foregoing discussion and examples merely provide a detailed description of some embodiments. It will therefore be apparent to those skilled in the art that various modifications and equivalents can be made without departing from the spirit and scope of the invention.

All journal articles, other references, patents, and patent applications identified in this patent application are incorporated herein by reference in their entirety.

Reference to the literature

1.Hausdorff WP,Bryant J,Paradiso PR,Siber GR.Which pneumococcal serogroups cause the most invasive disease:implications for conjugate vaccine formulation and use,part I.CHn Infect Dis 2000;30:100-21.

2.Hausdorff WP,Bryant J,Kloek C,Paradiso PR,Siber GR.The contribution of specific pneumococcal serogroups to different disease manifestations:implications for conjugate vaccine formulation and use,part I.CHn Infect Dis 2000;30:122-40.

(3.) while CG, farley MM, hadler J, et al, decline in innovative pneumatic radial area after the introduction of protein-polysaccharide conjugate vaccine. New Engl J Med 2003 (18): 1737-46.

Black S, shinefield H, hansen J, et al, postlichension evaluation of the effect of seven value, peadcal infection Dis 2001.

Robinson KA, baughman W, rothrock G, et al epidemic of infectious Streptococcus pneumoniae in the United States, 1995-1998.

Butler J, breiman R, lipman H, et al, serotype distribution of Streptococcus pneumoniae infections in the United States, 1978-1994J infection Dis 1995.

Whitney CG, farley MM, hadler J, et al, incorporated prediction of multidrug-resistant Streptococcus pneumoniae in the United states J Med 2000 343.

Hofmann J, cetron MS, farley MM, et al The prevalence of drug-resistant Streptococcus pneumaniae in Atlanta.N Engl J Med 1995 333.

9.Joloba ML,Windau A,Bajaksouzian S,Appelbaum PC Hausdorff WP,Jacobs MR.Pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in children with otitis media.CHn Infect Dis 2001;33:1489-94.

Black S, shinefield H, fireman B, et al effectiveness, safety, and immunogenicity of a latent macromolecular conjugate vaccine in children Infect Dis J2000.

11.Rudolph KM,Parkinson AJ,Reasonover AL,Bulkow LR,Parks DJ,Butler JC.Serotype distribution and antimicrobial resistance pattenrs of invasive isolates of Streptococcus pneumoniae:Alaska,1991-1998.JInfect Dis 2000;182:490-6.

12. Snaidack DH, schwartz B, lipman H, et al, positional interrelations for the prevention of development of bone pUnonia, geographic and temporal differences in servers and server up distribution of site plasmid, immunological for vaccine constructs, pediformer infection Dis J1995.

13.Fagan RL,Hanna JN,Messer RD,Brookes DL,Murphy DM.The epidemiology of invasive pneumococcal disease in children in Far North Queensland.J.Paediatr Child Health 2001;37:571-5.

Kertesz DA, di Fabio JL, de Cunto Brandilone MC, et al, inactive Streptococcus pneumoniae introduction in Latin American ladder: results of the Pan American Health Organization culture, CHn introduction Dis 1998 26.

15.Hausdorff W,Siber G,Paradiso P.Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children.Lancet 2001;357:950-52.

16.Buckingham SC,King MD,Miller ML.Incidence and etiologies of complicated parapneumonic effusions in children,1996to 2001.Pediatr Infect Dis J 2003;22:499-504.

Byington C1 Spencer L, johnson T, et al, antibiotic environmental introduction of a supplemented high rate of polypeptide paragenic investment, risk factors and microbial associations. Clin infection Dis2002; 434-40.

Tan T, mason E, waId E, et al Clinical characteristics with a compatible pneumoconia used by Streptococcus pneumaniae Pediatrics2002; 110.

19.Block SL, hedrick J, harrison CJ, et al, pneumococcal serotypes from access otitis media in road Kentucky. Pediatr Infect Dis J2002.

Hausdorff WP, yothers G, dagan R, et al, multi national study of heterocyclic using ingredient theory medium in child, pediatr Infect J2002.

Robbins JB, australian R, lee CJ, et al, constraints for formulating the second-generation genetic complex vaccine with the drugs on the cross-reactive types with groups J input Dis 1983.

22.Nahm MH,Olander JV,Magyarlaki M.Identification of cross-reactive antibodies with low opsonophagocytic activity for Streptococcus pneumoniae.J Infect Dis 1997;176:698-703.

23.Yu X,Gray B,Chang S,Ward Jl,Edwards KM,Nahm MH.Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants.J Infect Dis 1999;180:1569-76.

24.Vakevainen M,Eklund C,Eskola J,Kayhty H.Cross-reactivity of antibodies to type 6B and 6A polysaccharides of Streptococcus pneumoniae,evoked by pneumococcal conjugate vaccines,in infants.JInfect Dis 2001;184:789-93.

25.Ekstrom N,Kilpi T,Lahdenkari M1 Lehtonen H1 Ahman H,Kayhty,H.Immune response to cross-reacting pneumococcal serotypes6A/6B and 19A/19F in the FmOM vaccine trial,Third World of Congress of Pediatric Infectious Diseases,Santiago,Chile,November 19-23,2003.

26.Penn RL,Lewin EB,Douglas RG,Jr.,Schiffman G,Lee CJ,Robbins JB.Antibody responses in adult volunteers to pneumococcal polysaccharide types 19F and 19A administered singly and in combination.Infect Immυn 1982;36:1261-2.

27.Giebink GS,Meier JD,Quartey MK,Liebeler CL1 Le CT.lmmunogenicity and efficacy of Streptococcus pneumoniae polysaccharide-protein conjugate vaccines against homologous and heterologous serotypes in the chinchilla otitis media model.J Infect Dis1996;173:119-27.

28.Saeland E,Jakobsen H,lngolfsdottir G,Sigurdardottir ST,Jonsdottir I.Serum samples from infants vaccinated with a pneumococcal conjugate vaccine,PncT,protect mice against invasive infection caused by Streptococcus pneumoniae serotypes 6A and 6B.J Infect Dis 2001;183:253-60.

29.Jakobsen H,Sigurdsson VD,Sigurdardottir S,Schulz D,Jonsdottir I.Pneumococcal serotype 19F conjugate vaccine induces cross-protective immunity in serotype 19A in a murine pneumococcal pneumonia model.Infect lmmun 2003;71:2956-9.

30.Klugman KP,Madhi SA,Huebner RE,Kohberger R,Mbelle N,Pierce N.A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection.N Engl J Med 2003;349:1341-8.

O' Brien KL, moulton LH, reid R, et al effectiveness and safety of seven-value connected pulmonary vaccine in American Indian chip 2003, group random three. Lancet 2003, 355-61.

Eskola J, kilpi T, palmu A, et al, efficacy of a pneumococcal conjugate vaccine medium. N Engl J Med 2001.

Pilishvili T, farley M, vazquez M, reingold A, nyquist A, et al, efficient of crucial plasmid vaccine in children. Abst G-1079, ICAAC, chicago, IL,2003.

34. U.S. Pat. No.4,673,574.

35. U.S. Pat. No.4,902,506.

Claims

1. A multivalent immunogenic composition comprising: 13 different polysaccharide-protein conjugates, and a physiologically acceptable carrier, wherein each conjugate comprises a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to a carrier protein, and the capsular polysaccharides are prepared from serotypes 1,3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F, wherein the carrier protein is CRM ₁₉₇ And wherein conjugation is achieved by reductive amination, wherein the serotype 4 conjugate is obtained by purification of a capsular polysaccharide from Streptococcus pneumoniae serotype 4, the capsular polysaccharide being chemically activated such that it is capable of reacting with CRM ₁₉₇ Reacting, and wherein the activating comprises hydrolyzing the capsular polysaccharide with hydrochloric acid, and once activated, the capsular polysaccharide is conjugated to CRM ₁₉₇ To form the conjugate; wherein the serotype 6A conjugate is obtained by purification of a capsular polysaccharide from Streptococcus pneumoniae serotype 6A, the capsular polysaccharide being chemically activated such that it is capable of reacting with CRM ₁₉₇ Reacting, and wherein the activating comprises reducing the size of serotype 6A capsular polysaccharide prior to oxidation, which capsular polysaccharide, once activated, is conjugated to CRM ₁₉₇ To form the conjugate.

2. The immunogenic composition of claim 1, further comprising an adjuvant.

3. The immunogenic composition of claim 2, wherein the adjuvant is aluminum phosphate.

4. A multivalent immunogenic composition comprising: 13 different polysaccharide-protein conjugates, and a physiologically acceptable carrier, wherein each conjugate comprises a capsular polysaccharide from a different serotype of streptococcus pneumoniae conjugated to a carrier protein, and the capsular polysaccharides are derived from bloodSerotype 1,3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F wherein the carrier protein is CRM ₁₉₇ And wherein each 0.5ml dose is formulated to contain: 2.2. Mu.g of each saccharide, except 4.4. Mu.g of 6B; about 29 μ g CRM ₁₉₇ A carrier protein; 0.125mg elemental aluminum adjuvant; and sodium chloride and sodium succinate buffers as excipients, wherein the serotype 4 conjugate is obtained by purification of a capsular polysaccharide from streptococcus pneumoniae serotype 4, the capsular polysaccharide being chemically activated such that it is capable of reacting with CRM ₁₉₇ (ii) a reaction, and wherein the activation comprises hydrolysis of the capsular polysaccharide with hydrochloric acid, and once activated, the capsular polysaccharide is conjugated to CRM ₁₉₇ To form the conjugate; wherein the serotype 6A conjugate is obtained by purification of a capsular polysaccharide from Streptococcus pneumoniae serotype 6A, the capsular polysaccharide being chemically activated such that it is capable of reacting with CRM ₁₉₇ Reacting, and wherein the activating comprises reducing the size of serotype 6A capsular polysaccharide prior to oxidation, which capsular polysaccharide, once activated, is conjugated to CRM ₁₉₇ To form the conjugate.

5. The multivalent immunogenic composition of claim 4, comprising: 13 different polysaccharide-protein conjugates, and a physiologically acceptable carrier, wherein each conjugate comprises a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to a carrier protein, and the capsular polysaccharides are prepared from serotypes 1,3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F, wherein the carrier protein is CRM ₁₉₇ And wherein each 0.5ml dose is formulated to contain: 2.2. Mu.g of each saccharide, except 4.4. Mu.g of 6B; about 29 μ g CRM ₁₉₇ A carrier protein; 0.5mg of aluminum phosphate adjuvant; and sodium chloride and sodium succinate buffers as excipients, wherein the serotype 4 conjugate is obtained by purification of a capsular polysaccharide from streptococcus pneumoniae serotype 4, said capsular polysaccharide being chemically activated such that it is capable of reacting with CRM ₁₉₇ And wherein the activation comprises hydrolysis of the capsular polysaccharide with hydrochloric acid, and once activated, the capsular polysaccharideConjugation to CRM ₁₉₇ To form the conjugate; wherein the serotype 6A conjugate is obtained by purification of a capsular polysaccharide from Streptococcus pneumoniae serotype 6A, the capsular polysaccharide being chemically activated such that it is capable of reacting with CRM ₁₉₇ Reacting, and wherein the activating comprises reducing the size of serotype 6A capsular polysaccharide prior to oxidation, which capsular polysaccharide, once activated, is conjugated to CRM ₁₉₇ To form the conjugate.

6. The immunogenic composition of any one of claims 1-5 for use in inducing an immune response to a Streptococcus pneumoniae capsular polysaccharide conjugate.

7. The immunogenic composition of any one of claims 1-5 for use in vaccination.

8. The immunogenic composition of any one of claims 1-5 for use in vaccination wherein the subject receives one or several booster immunizations at sufficient intervals after the initial vaccination.

9. The immunogenic composition of any one of claims 1-5 for use in vaccination of infants and toddlers, wherein the vaccination regimen is at an age of 2, 4,6 and 12-15 months.

10. The immunogenic composition of any one of claims 1-5 for use in adolescent and adult vaccination.

11. A process for making a multivalent immunogenic composition, the composition comprising 13 different polysaccharide-protein conjugates, and a physiologically acceptable carrier, wherein each conjugate comprises a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to a carrier protein, and the capsular polysaccharides are prepared from serotypes 1,3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F, wherein the carrier protein is CRM ₁₉₇ Wherein the various glycoconjugates are mixed after purification to formulate the immunogenic composition, wherein the serumThe type 4 conjugate is obtained by purifying a capsular polysaccharide from streptococcus pneumoniae serotype 4, chemically activating the capsular polysaccharide such that the capsular polysaccharide is capable of reacting with CRM ₁₉₇ (ii) a reaction, and wherein the activation comprises hydrolysis of the capsular polysaccharide with hydrochloric acid, and once activated, the capsular polysaccharide is conjugated to CRM ₁₉₇ To form the conjugate; wherein the serotype 6A conjugate is obtained by purification of a capsular polysaccharide from Streptococcus pneumoniae serotype 6A, the capsular polysaccharide being chemically activated such that it is capable of reacting with CRM ₁₉₇ Reacting, and wherein the activating comprises reducing the size of serotype 6A capsular polysaccharide prior to oxidation, which capsular polysaccharide, once activated, is conjugated to CRM ₁₉₇ To form the conjugate.